Athira Pharma Inc., of Seattle, said it was awarded a research grant by the U.S. NIH that the company expects to total $15 million in a three-year period. The grant supports Athira’s lead candidate, ACT-AD, in a phase II trial for treating mild to moderate Alzheimer’s disease. The study will use quantitative electroencephalogram and event-related […]

Seattle-based biotech company Athira Pharmaannounced a three-year grant totaling $15 million from the National Institute on Aging to support an upcoming clinical trial of a treatment that seeks to stop the deterioration of neurons and restore healthy brain activity in people with mild to moderate cases of Alzheimer’s disease. The grant from the NIA, part […]

Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical trial with STRO-001, a CD74-targeted antibody-drug conjugate (ADC) developed by Sutro Biopharma and designed for the treatment of patients with late-line Non-Hodgkin Lymphoma (NHL), demonstrated that the investigational drug was generally well-tolerated in this patient population. […]